So the goal of the B12 component is correction and prevention: keeping levels from dropping during treatment, which can in turn help offset the fatigue, brain fog, and irritability that may otherwise show up around weeks 4 to 8 of GLP-1 treatment
Regulatory and safety status: It's pending FDA review and not currently approved for use in humans
Quick Reference: Standard Protocol Community-documented protocol: 250 mcg subcutaneous in the morning, 3 days per week, for 8-week cycles -- far below the 2.4 mg weekly clinical trial dose, reflecting conservative research-peptide practice
The immune system reacts to the infection, but over time it can accidentally begin attacking the stomach as well
If using both in the same routine, wait 15 to 20 minutes between applications
Results showed Cerebrolysin was significantly more effective than placebo for cognitive function at 4 weeks (SMD -0.40, p=0.003), global clinical change at both 4 weeks (OR 3.32, p=0.02) and 6 months (OR 4.98, p=0.015), and combined global benefit (cognitive + clinical) at both timepoints